Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK.

Kevin Bowrin,Jean-Baptiste Briere,Pierre Levy,Aurélie Millier,Jean Tardu,Mondher Toumi

Journal of market access & health policy（2020）

引用 5|浏览7

暂无评分

摘要

These results suggest that rivaroxaban and apixaban are cost-effective vs VKA, based on RWE, considering a £20,000 threshold, from the NHS and PSS perspective in the UK for stroke prevention in patients with NVAF. This economic evaluation may provide valuable information for decision-makers, in a context where RWE is more accessible and its value more acknowledged.

查看译文

关键词

Anticoagulants,atrial fibrillation,cost-effectiveness,economic,real-world evidence,stroke prevention

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要